Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma (Q35174141)

6 August 2017

1 reference

title

Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma (English)

1 reference

6 August 2017

0 references

Jamie H Von Roenn

1

1 reference

PubMed ID

12852654

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

Hematology / Oncology Clinics of North America

6 August 2017

1 reference

6 August 2017

17

1 reference

6 August 2017

3

1 reference

6 August 2017

747-762

1 reference

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Presentation of AIDS-related pulmonary Kaposi's sarcoma diagnosed by bronchoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Endoscopic examination in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical, radiographic, and pathologic manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Endobronchial lesions in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Pleural disease and acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Pleural disease in patients with acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Serosanguineous pleural effusions in AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Fine-needle aspiration diagnosis of Kaposi's sarcoma in a developing country

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Utility of HHV8 RNA detection for differentiating Kaposi's sarcoma from its mimics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Absence of an association between the presence of human herpesvirus 8 antibodies and the development of Kaposi's sarcoma in HIV-1-infected patients receiving antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Radiotherapy in the management of epidemic Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

The role of radiation therapy in the management of HIV-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Advanced acquired immune deficiency syndrome-related Kaposi's sarcoma. Results of pilot studies using combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

Treatment of classical Kaposi's sarcoma with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900043-1

7 January 2021

10.1016/S0889-8588(03)00043-1

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12852654